Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been completed and has reached its primary objectives of safety and tolerability of ATB-346, up to the maximum dose tested (1500 mg). The results of this portion of the Phase I program have met the corporation’s expectations based on extensive pre-clinical studies, and support the continuation of the Phase I program into the multiple ascending dose and food-effect portions, both of which are underway and are expected to be completed by January 2015.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s ATB-346 targets the global need for safer non-steroidal anti-inflammatory drugs (NSAIDs).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Antibe Therapeutics Inc.Dan Legault, 416-473-4095Chief Executive Officerdan.legault@antibethera.comwww.antibethera.com

Antibe Therapeutics (CE) (USOTC:ATBPF)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Antibe Therapeutics (CE)
Antibe Therapeutics (CE) (USOTC:ATBPF)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Antibe Therapeutics (CE)